牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-004353 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-22-000153 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-22-002156 Act: 33 Size: 293 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-001836 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ F-3 Registration statement by foreign private issuers Accession Number: 0001213900-22-001135 Act: 33 Size: 508 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-22-000605 Act: 34 Size: 27 KB 网页链接
$灿菲特生物制药(CANF)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-21-068127 Act: 33 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-067808 Act: 34 Size: 24 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-067180 Act: 34 Size: 207 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-21-066414 Act: 34 Size: 22 KB 网页链接